Selenium supplementation for patients with Graves� hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Graves' hyperthyroidism is an autoimmune disease causing hyperfunction of the thyroid gland. The concentration of selenium is high in the thyroid gland and two important groups of enzymes within the thyroid are selenoproteins, that is, they depend on selenium. Selenium may have beneficial effects on autoimmune hypothyroidism and on Graves' orbitopathy, but the effects of selenium on Graves' hyperthyroidism is unknown.We hypothesize that adjuvant selenium may be beneficial in the treatment of Graves' hyperthyroidism. The objective is to investigate if selenium supplementation plus standard treatment with anti-thyroid drugs versus standard treatment with anti-thyroid drugs will lead to a decrease in anti-thyroid drug treatment failure (that is, failure to remain euthyroid, without further treatment, one year after cessation of anti-thyroid drug treatment), faster and longer lasting remission (that is, anti-thyroid drug treatment success), and improved quality of life in patients with Graves' hyperthyroidism. METHODS AND DESIGN: The trial is an investigator-initiated, randomised, blinded, multicentre clinical trial. Inclusion criteria are: age 18 years or older; diagnosis of active Graves' hyperthyroidism within the last two months; and informed consent. Exclusion criteria are major co-morbidity; previous radioactive iodine treatment; ongoing anti-thyroid drug treatment for more than two months; treatment with immunomodulatory drugs; known allergy towards the components in the selenium and placebo pills; pregnancy or breast-feeding; and intake of selenium supplementation above 70 μg per day. We plan to include 492 participants, randomised (1:1) to two tablets of 100 μg selenium once daily for the 24 to 30 months intervention period versus two identical placebo tablets once daily.The primary outcome is the proportion of participants with anti-thyroid drug treatment failure (see above) at the end of the intervention period (24 to 30 months). Secondary outcomes are: thyroid-specific quality of life during the first year after randomisation; level of thyroid stimulating hormone-receptor antibodies at 18 months after randomisation and at the end of the intervention period (24 to 30 months); hyperthyroid symptoms during the first year after randomisation; eye symptoms during the first year after randomisation, and at the end of the intervention period (24 to 30 months); adverse reactions during the intervention period; and serious adverse events during the intervention period. DISCUSSION: It was of great importance to the initiators of this trial, that the results would be directly applicable to daily clinical practice. Therefore, it was designed as a pragmatic trial: the patients follow their usual treatment at their usual hospitals. In order to still collect high quality data on the clinical course and quality of life, an elaborate trial management system was designed to keep track of patient input, need for trial personnel input and action, and to collect data from medical chart systems. Meticulous follow-up on missing responses to the QoL measurements has been incorporated into the system, to minimise missing quality of life data. Monitoring of adverse reactions and events is achieved by thorough instruction of the participants, surveillance of patient-reported outcomes, and integration with national databases regarding hospitalizations. A very long intervention period was necessary, since patients are not considered in remission until one year after stopping anti-thyroid drugs. Usually, patients are treated for 12 to 18 months with anti-thyroid drugs, yielding a total intervention period of 24 to 30 months. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01611896.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gärtner, R., Gasnier, B. C. H., Dietrich, J. W., Krebs, B., & Angstwurm, M. W. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8421 · Cited by 389 · cited 1×
“In six [14-19] of seven [14-20] placebo-controlled clinical trials, selenium treatment reduced thyroid peroxidase antibody (TPOAb) levels, indicating a beneficial effect on the autoimmune activity.”
Background
Cited by
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
Self-citationKöhrle, J. (2015) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000190 · Cited by 195
Watt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1322 · Cited by 152
“To compare higher-order summary measures of the two instruments, responsiveness of a ThyPRO Composite score constructed for two clinical trials (44, 45) was compared with the SF-36 Health Survey Mental Component Summary (MCS).”
MethodSelf-citationDevelopment of a Short Version of the Thyroid-Related Patient-Reported Outcome ThyPRO
Watt, T., Bjorner, J. B., Groenvold, M., Cramon, P., Winther, K. H., Hegedüs, L., Bonnema, S. J., Rasmussen, Å. K., Ware, J. E., & Feldt-Rasmussen, U. (2015) · Thyroid · doi:10.1089/thy.2015.0209 · Cited by 132
Self-citationWinther, K. H., Bonnema, S. J., Cold, F., Debrabant, B., Nybo, M., Cold, S., & Hegedüs, L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0069 · Cited by 88
Self-citation
Metadata
- Authors
- Watt, T., Cramon, P., Bjorner, J., Bonnema, S., Feldt-Rasmussen, U., Gluud, C., Gram, J., Hansen, J., Heged�s, L., Knudsen, N., Bach-Mortensen, P., Nols�e, R., Nygaard, B., Pociot, F., Skoog, M., Winkel, P., & Rasmussen, �.
- Venue
- Trials
- Published
- 2013
- Volume
- 14
- Issue
- 1
- Pages
- 119
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2128019213
- Cited by
- 69
- References
- 1
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selenium supplementation for patients with Graves� hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-14-119
- The paper
- Watt, T., Cramon, P., Bjorner, J., Bonnema, S., Feldt-Rasmussen, U., Gluud, C., Gram, J., Hansen, J., Heged�s, L., Knudsen, N., Bach-Mortensen, P., Nols�e, R., Nygaard, B., Pociot, F., Skoog, M., Winkel, P., & Rasmussen, �. (2013). Selenium supplementation for patients with Graves� hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-14-119
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.